3 completed, 3 recruiting, 1 active not recruiting, 1 not yet recruiting. 8 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 3, Recruiting 3, Active not recruiting 1, Not yet recruiting 1 |
| Phase 1 | 1 | Completed 1 |
Follow relacorilant: new trials by email Literature Review of relacorilant trials Research Report on relacorilant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Relacorilant and Nab-Paclitaxel in Recurrent or Metastatic Cervical Cancer Relacorilant, Nab-paclitaxel - Recurrent or Metastatic Cervical Cancer | Phase 2 | Not yet recruiting | ARCAGY/ GINECO GROUP | 63 | 2026-10-01 | 2026-08-13 |
| Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma Relacorilant, Nab-paclitaxel, Gemcitabine - Adenocarcinoma, Carcinoma, Pancreatic Ductal | Phase 2 | Recruiting | Corcept Therapeutics | 80 | 2026-01-27 | 2026-09-25 |
| Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers Relacorilant 150 mg once daily (QD), Nab-paclitaxel 80 mg/m^2, Bevacizumab 10 mg/kg - Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Recruiting | Corcept Therapeutics | 270 | 2025-04-11 | 2026-07-16 |
| A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer Relacorilant, Enzalutamide, Placebo (Sugar Pill) - Prostate Cancer, Prostate Adenocarcinoma | Phase 2 | Recruiting | University of Chicago | 90 | 2025-01-06 | 2026-08-31 |
| Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Relacorilant, Nab-paclitaxel - Recurrent Ovarian Cancer, Recurrent Fallopian Tube Carcinoma | Phase 2 | Completed | Corcept Therapeutics | 178 | 2019-04-05 | 2025-10-07 |
| Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome relacorilant - Cushing Syndrome | Phase 2 | Active not recruiting | Corcept Therapeutics | 125 | 2018-05-07 | 2026-10-09 |
| Study to Evaluate CORT125134 in Participants With Cushing's Syndrome CORT125134 - Cushing's Syndrome | Phase 2 | Completed | Corcept Therapeutics | 35 | 2016-06-01 | 2019-10-15 |
| Study to Evaluate Relacorilant (CORT125134) in Combination With Nab-paclitaxel in Participants With Solid Tumors Relacorilant with nab-paclitaxel - Solid Tumors | Phase 1 / Phase 2 | Completed | Corcept Therapeutics | 85 | 2016-05-23 | 2022-12-06 |
ACTH Syndrome, Ectopic (2) · Adrenal Cortex Neoplasms (2) · Adrenocortical Carcinoma (2) · Cushing Syndrome (2) · Diabetes Mellitus, Type 2 (2) · Fallopian Tube Neoplasms (2) · Hypertension (2) · Ovarian Neoplasms (2) · Pituitary ACTH Hypersecretion (2) · Adenocarcinoma (1) · Carcinoma, Ovarian Epithelial (1) · Carcinoma, Pancreatic Ductal (1) · Endometrial Neoplasms (1) · Fallopian Tube Diseases (1) · Genital Neoplasms, Female (1)
Corcept Therapeutics (6) · ARCAGY/ GINECO GROUP (1) · University of Chicago (1)
United States (7) · Italy (4) · Spain (3) · Belgium (2) · Canada (2) · France (2) · Germany (2) · Netherlands (2) · Poland (2) · Austria (1) · Hungary (1) · Israel (1) · Romania (1) · South Korea (1) · United Kingdom (1)
Andreas G Moraitis, MD (1) · Danny Nguyen (1) · Danny Nguyen, MD (1) · John McNally (1) · Russell Szmulewitz, MD (1) · Sachin Pai, MD (1)